Vitamin D (VitD) properties can impact cancer cells. Despite the documented link between VitD levels and prevalence of several cancer types, conflicting findings have been reported for cutaneous melanoma (CM).
Objective:
This overview aims to compile the evidence from existing systematic reviews and meta-analyses, emphasizing the relationships between VitD serum levels, intake, receptor (VDR) gene polymorphisms, and CM risk.
Methods:
A literature search in electronic databases was conducted, based on certain inclusion criteria.
Results:
Twenty-one studies were included. Conflicting evidence between high VitD serum levels, dietary/supplementary intake, and CM risk is highlighted. VDR polymorphisms may play a role in the intricate CM pathogenesis. Also, high serum levels of VitD are associated with improved CM prognosis.
Conclusions:
This overview showed that the impact of VitD on CM is not clear, and thus further research is suggested to explore its true effect size on CM risk.
Get full access to this article
View all access options for this article.
References
1.
VillaniA, FabbrociniG, CostaC, et al.Melanoma screening days during the coronavirus disease 2019 (COVID-19) pandemic: Strategies to adopt. Dermatol Ther (Heidelb), 2020; 10(4):525–527; doi: 10.1007/s13555-020-00402-x.
2.
SchadendorfD, van AkkooiACJ, BerkingC, et al.Melanoma. Lancet, 2018; 392(10151):971–984; doi: 10.1016/s0140-6736(18)31559-9.
GandiniS, AutierP, BoniolM. Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol, 2011; 107(3):362–366; doi: 10.1016/j.pbiomolbio.2011.09.011.
5.
BoniolM, AutierP, BoyleP, et al.Cutaneous melanoma attributable to sunbed use: Systematic review and meta-analysis. BMJ, 2012; 345:e4757; doi: 10.1136/bmj.e4757.
6.
BerwickM, ErdeiE, HayJ. Melanoma epidemiology and public health. Dermatol Clin, 2009; 27(2):205–214, viii; doi: 10.1016/j.det.2008.12.002.
7.
van der LeestRJ, FlohilSC, ArendsLR, et al.Risk of subsequent cutaneous malignancy in patients with prior melanoma: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol, 2015; 29(6):1053–1062; doi: 10.1111/jdv.12887.
8.
JiangAJ, RambhatlaPV, EideMJ. Socioeconomic and lifestyle factors and melanoma: A systematic review. Br J Dermatol, 2015; 172(4):885–915; doi: 10.1111/bjd.13500.
9.
SiegelRL, MillerKD, WagleNS, et al.Cancer statistics, 2023. CA Cancer J Clin, 2023; 73(1):17–48; doi: 10.3322/caac.21763.
10.
JeonSM, ShinEA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med, 2018; 50(4):1–14; doi: 10.1038/s12276-018-0038-9.
11.
GarlandCF, GarlandFC, GorhamED, et al.The role of vitamin D in cancer prevention. Am J Public Health, 2006; 96(2):252–261; doi: 10.2105/ajph.2004.045260.
12.
ZhangL, WangS, CheX, et al.Vitamin D and lung cancer risk: A comprehensive review and meta-analysis. Cell Physiol Biochem, 2015; 36(1):299–305; doi: 10.1159/000374072.
HolickMF. Vitamin D deficiency. N Engl J Med, 2007; 357(3):266–281; doi: 10.1056/NEJMra070553.
15.
PollockM, FernandesRM, BeckerLA, et al.Chapter V: Overviews of Reviews. In: Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). (Higgins JPT, Thomas J, Chandler J, et al. eds.) Cochrane; 2023. Available from: www.training.cochrane.org/handbook.
16.
BougioukasKI, BourasE, Apostolidou-KioutiF, et al.Reporting guidelines on how to write a complete and transparent abstract for overviews of systematic reviews of health care interventions. J Clin Epidemiol, 2019; 106:70–79; doi: 10.1016/j.jclinepi.2018.10.005.
17.
SheaBJ, ReevesBC, WellsG, et al.AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017; 358:j4008; doi: 10.1136/bmj.j4008.
18.
PollockM, FernandesRM, NewtonAS, et al.A decision tool to help researchers make decisions about including systematic reviews in overviews of reviews of healthcare interventions. Syst Rev, 2019; 8(1):29; doi: 10.1186/s13643-018-0768-8.
19.
PieperD, AntoineSL, MathesT, et al.Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol, 2014; 67(4):368–375; doi: 10.1016/j.jclinepi.2013.11.007.
20.
BougioukasKI, DiakonidisT, MavromanoliAC, et al.ccaR: A package for assessing primary study overlap across systematic reviews in overviews. Res Synth Methods, 2022; doi: 10.1002/jrsm.1610.
21.
org/RCTJhwR-p. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria; 2016.
22.
ShellenbergerRA, GowdaS, KurnH, et al.Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: A systematic review and meta-analysis. Melanoma Res, 2023; 33(4):265–274; doi: 10.1097/cmr.0000000000000897.
23.
SongY, LuH, ChengY. To identify the association between dietary vitamin D intake and serum levels and risk or prognostic factors for melanoma-systematic review and meta-analysis. BMJ Open, 2022; 12(8):e052442; doi: 10.1136/bmjopen-2021-052442.
24.
TsaiTY, KuoCY, HuangYC. The association between serum vitamin D level and risk and prognosis of melanoma: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol, 2020; 34(8):1722–1729; doi: 10.1111/jdv.16189.
25.
Mahamat-SalehY, AuneD, SchlesingerS. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: A systematic review and dose-response meta-analysis of prospective studies. Sci Rep, 2020; 10(1):13151; doi: 10.1038/s41598-020-70078-y.
26.
FortesC. Are anti-inflammatory foods associated with a protective effect for cutaneous melanoma?. Eur J Cancer Prev, 2020; 29(5):466–469; doi: 10.1097/cej.0000000000000591.
27.
BirkeM, SchöpeJ, WagenpfeilS, et al.Association of vitamin D receptor gene polymorphisms with melanoma risk: A meta-analysis and systematic review. Anticancer Res, 2020; 40(2):583–595; doi: 10.2187/3/anticanres.13988.
28.
VasiloviciAF, GrigoreLE, UngureanuL, et al.Vitamin D receptor polymorphisms and melanoma. Oncol Lett, 2019; 17(5):4162–4169; doi: 10.3892/ol.2018.9733.
29.
LeeYH, Gyu SongG. Vitamin D receptor FokI, BsmI, TaqI, ApaI, and EcoRV polymorphisms and susceptibility to melanoma: A meta-analysis. J Buon, 2015; 20(1):235–243.
30.
HouW, WanX, FanJ. Variants Fok1 and Bsm1 on VDR are associated with the melanoma risk: Evidence from the published epidemiological studies. BMC Genet, 2015; 16:14; doi: 10.1186/s12863-015-0163-6.
31.
de WaureC, QuarantaG, GualanoMR, et al.Systematic review of studies investigating the association between dietary habits and cutaneous malignant melanoma. Public Health, 2015; 129(8):1099–1113; doi: 10.1016/j.puhe.2015.06.015.
32.
ZhaoXZ, YangBH, YuGH, et al.Polymorphisms in the vitamin D receptor (VDR) genes and skin cancer risk in European population: A meta-analysis. Arch Dermatol Res, 2014; 306(6):545–553; doi: 10.1007/s00403-014-1464-8.
33.
XuY, HeB, PanY, et al.Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Tumour Biol, 2014; 35(5):4153–4169; doi: 10.1007/s13277-013-1544-y.
34.
GandiniS, GnagnarellaP, SerranoD, et al.Vitamin D receptor polymorphisms and cancer. Adv Exp Med Biol, 2014; 810:69–105; doi: 10.1007/978-1-4939-0437-2_5.
35.
CainiS, BoniolM, TostiG, et al.Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: A comprehensive review and meta-analysis. Eur J Cancer, 2014; 50(15):2649–2658; doi: 10.1016/j.ejca.2014.06.024.
36.
OrlowI, RoyP, ReinerAS, et al.Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer, 2012; 130(2):405–418; doi: 10.1002/ijc.26023.
37.
DenzerN, VogtT, ReichrathJ. Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. Dermatoendocrinol, 2011; 3(3):205–210; doi: 10.4161/derm.3.3.16519.
38.
ButtiglieroC, MonaghedduC, PetroniP, et al.Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: A systematic review. Oncologist, 2011; 16(9):1215–1227; doi: 10.1634/theoncologist.2011-0098.
39.
Randerson-MoorJA, TaylorJC, ElliottF, et al.Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer, 2009; 45(18):3271–3281; doi: 10.1016/j.ejca.2009.06.011.
40.
KöstnerK, DenzerN, MüllerCS, et al.The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: A review of the literature. Anticancer Res, 2009; 29(9):3511–3536.
41.
GandiniS, RaimondiS, GnagnarellaP, et al.Vitamin D and skin cancer: A meta-analysis. Eur J Cancer, 2009; 45(4):634–641; doi: 10.1016/j.ejca.2008.10.003.
42.
MocellinS, NittiD. Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: A systematic review and meta-analysis. Cancer, 2008; 113(9):2398–2407; doi: 10.1002/cncr.23867.
43.
TangJY, FuT, LeblancE, et al.Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: Post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol, 2011; 29(22):3078–3084; doi: 10.1200/jco.2011.34.5967.
44.
SunX, ZhangN, YinC, et al.Ultraviolet radiation and melanomagenesis: From mechanism to immunotherapy. Front Oncol, 2020; 10:951; doi: 10.3389/fonc.2020.00951.
45.
GilchrestBA, EllerMS, GellerAC, et al.The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med, 1999; 340(17):1341–1348; doi: 10.1056/nejm199904293401707.
46.
FakihMG, TrumpDL, JohnsonCS, et al.Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis, 2009; 24(2):219–224; doi: 10.1007/s00384-008-0593-y.
47.
RobsahmTE, SchwartzGG, TretliS. The inverse relationship between 25-hydroxyvitamin D and cancer survival: Discussion of causation. Cancers (Basel), 2013; 5(4):1439–1455; doi: 10.3390/cancers5041439.
48.
BurnsEM, ElmetsCA, YusufN. Vitamin D and skin cancer. Photochem Photobiol, 2015; 91(1):201–209; doi: 10.1111/php.12382.
49.
SeretisK, BounasN, GaitanisG, et al.A meta-analysis on the impact of the COVID-19 pandemic on cutaneous melanoma diagnosis in Europe. Cancers (Basel), 2022; 14(24); doi: 10.3390/cancers14246085.
50.
SeretisK, BoptsiE, BoptsiA, et al.The impact of treatment delay on skin cancer in COVID-19 era: A case-control study. World J Surg Oncol, 2021; 19(1):350; doi: 10.1186/s12957-021-02468-z.
51.
ZeljicK, Kandolf-SekulovicL, SupicG, et al.Melanoma risk is associated with vitamin D receptor gene polymorphisms. Melanoma Res, 2014; 24(3):273–279; doi: 10.1097/CMR.0000000000000065.
52.
SantonocitoC, CapizziR, ConcolinoP, et al.Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol, 2007; 156(2):277–282; doi: 10.1111/j.1365-2133.2006.07620.x.
53.
LiC, LiuZ, WangLE, et al.Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: A case-control study. Int J Cancer, 2008; 122(9):2077–2084; doi: 10.1002/ijc.23357.
54.
LiC, LiuZ, ZhangZ, et al.Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol, 2007; 127:276–280.
55.
WyattC, LucasRM, HurstC, et al.Vitamin D deficiency at melanoma diagnosis is associated with higher Breslow thickness. PLoS One, 2015; 10(5):e0126394; doi: 10.1371/journal.pone.0126394.
56.
OgbahZ, VisaL, BadenasC, et al.Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona. BMC Med Genet, 2013; 14:26; doi: 10.1186/1471-2350-14-26.
57.
HutchinsonPE, OsborneJE, LearJT, et al.Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res, 2000; 6(2):498–504.
58.
GapskaP, ScottRJ, Serrano-FernandezP, et al.Vitamin D receptor variants and the malignant melanoma risk: A population-based study. Cancer Epidemiol, 2009; 33(2):103–107; doi: 10.1016/j.canep.2009.06.006.
59.
HalsallJA, OsborneJE, PotterL, et al.A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br J Cancer, 2004; 91(4):765–770; doi: 10.1038/sj.bjc.6602006.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
